Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted therapies in HCC

Published: 21 January 2017

Recent Videos

video

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

Dr. Gordan, Florida Cancer Specialists and Research Institute, describes his concerns with PBMs as they affect community oncology practices

video

Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care

Dr. Burris, President, Clinical Operations, Sarah Cannon, considers liquid biopsies and their role in cancer care

video

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

Dr. Patton, Chief Executive Officer, Tennessee Oncology, outlines the “four pillars” Tennessee Oncology has adopted as a result of participation ...

video

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

Dr. Gordan, Florida Cancer Specialists and Research Institute, discusses how 340B has impacted the physicians and practices in his geography

video

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, describes how community oncologists can get their patients involved in the COA Patient ...

video

Jeff Patton, MD, reflects on how his practice manages the transition to value-based care

Dr. Patton, Chief Executive Officer, Tennessee Oncology, elaborates on how a large practice like Tennessee Oncology, with the associated financial ...

video

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, shares an example of how patients and the COA Patient Advocacy Network can ...

video

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, lists the ways community oncology contributes to the Cancer Moonshot

video

Ted Okon describes how PBMs affect oncologists and cancer patients

Ted Okon, Executive Director, Community Oncology Alliance, outlines the impact PBMs have on oncologists and cancer patients

video

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, shares a few of the most significant changes ...

video

Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders

Robert Baird Jr., RN, MSA, CASC, Chief Executive Officer, Dayton Physicians Network, elaborates on how his practice has been forging ...

video

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, shares how OCM ...

video

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, explains what practices ...

video

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, comments on how clinical trials are able to help physicians take ...

video

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses how clinical pathways are helping with value-based efforts at Tennessee Oncology

video

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers recommendations for community oncologists when thinking about ...

video

Bruce Feinberg, DO, comments on site of care and its impact on cancer economics

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, offers his opinion on site of care and ...

video

Bruce Feinberg, DO, shares his special interest in value-based care

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses his current area of interest in the ...

video

Ted Okon lists key takeaways from the 2017 COA meeting

Ted Okon, Executive Director, Community Oncology Alliance, provides highlights from the COA 2017 Community Oncology Conference

video

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, on how community oncology has contributed and advanced clinical research

video

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

Dr. Wilfong, Director of Quality Programs for Texas Oncology; Physician Champion for OCM at McKesson Specialty Health, reveals how OCM ...

video

Debra Patt, MD, shares how community oncology has contributed to advances in population health

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, reveals how community oncology has contributed to advances in population health

video

Debra Patt, MD, on technological advances in cancer care and community oncology

Dr. Patt, MPH, MBA, Vice President, Texas Oncology, discusses how technological advances in cancer care have been advanced by community ...

video

Ben Jones gives advice to practices interested in advocating for community oncology

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, addresses health care provides and practices that want ...

video

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

Dr. Burris, President, Clinical Operations, Sarah Cannon, offers insight into how clinical pathways impact prescribing decisions

video

Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place

Dr. Burris, President, Clinical Operations, Sarah Cannon, considers the role of oral oncolytics in the treatment of cancer patients

video

Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains how moving to a hospital outpatient setting has changed the ...

video

Bobbi Buell on the implications of mistakes in coding

Bobbi Buell, Code Mistress, onPoint Oncology, elaborates on the implications of mistakes in coding

video

Ben Jones on the hot policy topics impacting the delivery of quality cancer care

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, offers his thoughts on the hot policy topics ...

video

Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive

Ben Jones, Vice President, Government Relations and Public Policy, McKesson Specialty Health, details what McKesson Specialty Health is doing to ...

video

Edward Li on the status of the biosimilars regulatory pathway

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses the status of the biosimilars ...

video

Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology

Dr. Feinberg, VP Medical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, sheds light on some of the ways Cardinal ...

video

Skip Burris, MD, on the impact of OCM on large community practices

Dr. Burris, President, Clinical Operations, Sarah Cannon, comments on the impact of OCM on large community practices and, specifically, those ...

video

Edward Li outlines the legal challenges surrounding biosimilars and market entry

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, describes the legal challenges surrounding biosimilars ...

video

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses how pathways have impacted oncology ...

video

Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, on the advantages and disadvantages of a Professional Services Agreement ...

video

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, focuses on the amount of drug spending in total oncology ...

video

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are ...

video

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

Dr. Patton, Chief Executive Officer, Tennessee Oncology, discusses the impact of OCM on the prescribing of oral cancer agents

video

Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics

Dr. Patton, Chief Executive Officer, Tennessee Oncology, shares his thoughts on the impact of oral cancer agents on practice economics

video

Edward Li considers how comfortable medical oncologists and patients should be with biosimilars

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, offers his opinion on whether medical ...

video

Bobbi Buell offers advice to practices on how to guarantee good coding

Bobbi Buell, Code Mistress, onPoint Oncology, offers advice to practices to assure good coding

video

Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, recommends how oncologists should leverage data to better utilize claims data

video

Ted Okon shares the latest news on the 340B policy

Ted Okon, Executive Director, Community Oncology Alliance, discusses the latest on the 340B policy in Washington, D.C.

video

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on why independent community oncology practices join a hospital ...

video

Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, shares the evolution of his practice toward the current business ...

video

Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, discusses the business arrangements available to community oncologists who are ...

video

Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, comments on how quality of care can change when cancer ...

video

Edward Li on how clinical pathways are making progress towards their original goals

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, elaborates on whether clinical pathways are ...

video

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, examines the rate of oncology spending compared to the total ...

video

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, describes how his small practice manages to thrive in today’s ...

video

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, details the scope of the problem with DIR fees ...

video

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, shares with community oncologists across the country what he ...

video

Ray Bailey explains how he works with payers to dispense oral cancer agents to patients

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, shares how he works with payers to make sure ...

video

Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, elaborates on the novel approaches to adherence FCS has ...

video

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, elaborates on what COA is doing to help resolve ...

video

Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting

Dr. Lynch, Medical Oncologist, Warren Clinic Medical Oncology, Tulsa, OK, describes his experience working with patients in the hospital outpatient ...

video

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

Dr. Atkins, Medical Oncologist, Augusta Oncology Associates, lists the goals of the COA Patient Advocacy Network and how the organization ...

video

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

Dr. Vacirca, President, Community Oncology Alliance, CEO, New York Cancer Specialists, describes the efforts of COA to address DIR fees ...

video

Matt Farber provides insight on the evolution of specialty pharmacies

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies are evolving to meet the unique needs ...

video

Matt Farber describes how specialty pharmacies differ

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, on whether all specialty pharmacies are the same and are associated ...

video

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

Dr. Gordan, Florida Cancer Specialists and Research Institute, shares his thoughts on how practices can improve participation in clinical trials, ...

video

Lucio Gordan, MD, reflects on how he sees community oncology using big data

Dr. Gordan, Florida Cancer Specialists and Research Institute, on how he envisions community oncology utilizing big data

video

Lucio Gordan, MD, on how community oncology practices can utilize their own data

Dr. Gordan, Florida Cancer Specialists and Research Institute, debriefs community oncology practices on how to utilize their own data to ...

video

Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, explains how specialty pharmacies work with payers to help deliver cancer ...

video

James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, offers his recommendation for practices to manage unstructured data in order ...

video

James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares his opinion on how physicians can be more efficient in ...

video

James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges

Dr. Hamrick, Medical Oncologists, Senior Medical Director, Flatiron Health, shares how the EMR can solve quality reporting challenges and improve ...

video

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

Matt Farber, Senior Director, Oncology Disease State, Walgreen Co, describes the role specialty pharmacy plays in delivering quality cancer care

video

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how clinical pathways impact treatment decisions at FCS

video

Brad Prechtl on the keys to success for Florida Cancer Specialists

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, offers his opinion on the keys to success for FCS

video

Brad Prechtl offers his opinion on how size influences community oncology practices

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, on whether or not size matters when it comes to ...

video

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, explains the difference in cost of cancer care between the hospital ...

video

Skip Burris, MD, offers his opinion on molecular profiling patients

Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not clinicians should continue to molecular profile patients with the ...

video

William Harwin, MD, describes the shift from fee for service to value-based care

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, explains the transition from fee for service to value-based care ...

video

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, shares how FCS has evolved since participating in OCM

video

Bobbi Buell explains how practices can avoid the most common mistakes in billing

Bobbi Buell, Code Mistress, onPoint Oncology, shares the most common mistakes in billing, and how practices can overcome these mistakes

video

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

Ray Bailey, RPh, Pharmacy Director, Rx To Go, Florida Cancer Specialists, provides insight into how participation in OCM impacts the ...

video

William Harwin, MD, on working with local payers to deliver quality care

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, elaborates on how FCS is working with local payers to ...

video

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

Dr. Eagle, Past President, Community Oncology Alliance, Lake Norman Oncology, explains how operating in a small community oncology practice differs ...

video

Skip Burris, MD, offers his opinion on searching for rare mutations

Dr. Burris, President, Clinical Operations, Sarah Cannon, on whether or not it is worth the time and expense to search ...

video

William Harwin, MD, explains how he manages the quality measures required for OCM

Dr. Harwin, President & Managing Partner at Florida Cancer Specialists, offers insight into how FCS aggregate all the quality measures ...

video

Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses what the AMA is doing to help all physicians ...

video

Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, on what she would like to accomplish if she became ...

video

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, shares her concerns with the way OCM is progressing at ...

video

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses 1 sided and 2 sided risk associated with participation ...

video

Brad Prechtl explains how “shared savings” works between FCS and a local payer

Brad Prechtl, MBA, Chief Executive Officer of Florida Cancer Specialists, elaborates on how “shared savings” works between Florida Cancer Specialists ...

video

Barbara McAneny, MD, explains how the AMA and community oncology should interact

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, explains how the AMA and community oncology should interact

video

Bobby Green, MD, explains how he defines big data

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, explains how he defines big data

video

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

Dr. Green, Senior Vice President, Clinical Oncology, Flatiron Health, on how oncologists can leverage data to understand real quality care

video

Ricky Newton describes the paper COA is releasing on patient experiences with PBMs

Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes the paper COA is releasing at this year’s meeting ...

video

Ricky Newton provides an example of how a PBM is impacting cancer patient care

Ricky Newton, CPA, Director of Financial Services & Operations, COA, provides an example of how a PBM is impacting cancer ...

video

Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today

Ricky Newton, CPA, Director of Financial Services & Operations, COA, describes what happened with CVS last year and how COPA ...

video

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

Ricky Newton, CPA, Director of Financial Services & Operations, COA, tells us how COA is addressing the PBM DIR fees ...

video

Barbara McAneny, MD, discusses novel payer initiatives she finds interesting

Dr. McAneny, Chief Executive Officer, New Mexico Oncology Hematology Consultants, discusses novel payer initiatives she finds interesting

video

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added ...

video

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains what physicians need to know ...

video

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

Dr. Shore, MD, Director, Carolina Urologic Research Center, details how CHAARTED and STAMPEDE influenced his treatment of metastatic hormone sensitive ...

video

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses intriguing data and presentations from ASCO GU.

video

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, gives information ...

video

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, gives his views on which specific drugs have ...

video

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on how ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains how the treatment of advanced prostate cancer ...

video

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way ...

video

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has ...

video

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.

video

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, relays the ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, shares his thoughts on how to integrate multiple ...

video

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, briefly relays the data and conclusions from ...

video

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, describes the biggest challenges facing patients and providers in the diagnosis ...

video

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, discusses the results of his ASCO GU poster session.

video

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

Dr. Shore, MD, Director, Carolina Urologic Research Center, describes where chemotherapy fits into treatment for prostate cancer.

video

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses treatment trends in urology for 2017 and beyond.

video

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, provides insight into how immunotherapies are being integrated into renal cell ...

video

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, provides her opinion on how a commercial ...

video

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, explains his views on why some bladder cancer ...

video

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, relays the top line results for the ...

video

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, provides his ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains which metastatic castration-resistant prostate cancer patients, are ...

video

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center on how CHAARTED and STAMPEDE impacted her ...

video

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on how immunotherapies are being integrated into renal cell carcinoma ...

video

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains how genomics are helping physicians ...

video

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, discusses what physicians ...

video

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

Dr. Shore, MD, Director, Carolina Urologic Research Center, on which metastatic castration-resistant prostate cancer patients should receive chemotherapy.

video

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, explains the impact his data, as presented in “General ...

video

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, explains the types of metastatic renal cell carcinoma patients that should ...

video

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, discusses the ...

video

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, opines on whether non-invasive imaging is ready for ...

video

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, discusses how the surgery, radiation, and active ...

video

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, explains how ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, weighs in on if genetic testing for BRCA1 ...

video

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, on the fit of chemotherapy for prostate ...

video

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on the optimistic view of using immunotherapies to treat renal ...

video

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, provides his ...

video

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...

video

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his view on how side effects ...

video

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, weighs in ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, discusses how CHAARTED and STAMPEDE influences his treatment ...

video

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the ...

video

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his thoughts on the most exciting ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers feedback on if immunotherapy will be added ...

video

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, describes the ...

video

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, describes how genomics are changing the ...

video

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, reveals highlights from ...

video

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

Dr. Holzbeierlein, Associate Professor of Urology, University of Kansas Hospital, describes the data and conclusions he presented in “General Session ...

video

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, offers his opinion on whether or not BRCA1 and BRCA2 genetic testing ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

Nicholas J. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on the impact a commercial AR-V7 test ...

video

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

Dr. Shore, MD, Director, Carolina Urologic Research Center, explains how an AR-V7 commercial test will affect initial and subsequent choice ...

video

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

Dr. Saunders, Chief Executive Officer, Integra Connect, explains how the movement towards value-based care is driving technology innovation in oncology.

video

Charles Saunders, MD, considers EHR providers in an era of value-based care

Dr. Saunders, Chief Executive Officer, Integra Connect, offers his opinion on what EHR providers have missed in terms of supporting ...

video

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

Dr. Saunders, Chief Executive Officer, Integra Connect, explains the kind of operational transformation that will be required of oncologists to ...

video

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, weighs in ...

video

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

Dr. Vaishampayan, Department of Oncology, Karmanos Cancer Institute, discusses the most intriguing research presented at ASCO GU.

video

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses the impact genomics have in the way ...

video

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, offers key takeaways and highlights from ...

video

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, offers thoughts on ...

video

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on where chemotherapy fits into treatment for prostate cancer

video

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

David J. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, relays the importance of genomics to help ...

video

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

Dr. Hamdy, Head of the Nuffield Department of Surgery, University of Oxford, explains how the ProtecT study was designed.

video

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

Dr. Den, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on which topics ...

video

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

Dr. Aparicio, Associate Professor, The University of Texas MD Anderson Cancer Center, provides insight into who the right metastatic castration-resistant ...

video

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

Dr. Lalani, Medical Oncology, Dana Farber Cancer Institute, on the most intriguing research presentations here at ASCO GU.

video

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

Dr. Jonasch, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, ...

video

Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions

Jonathan Hirsch, President and Founder, Syapse, on precision medicine software helping oncologists make therapeutic decisions at the point of care

video

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

Jonathan Hirsch, President and Founder, Syapse, discusses how precision medicine is being used to help improve cancer treatment

video

Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information

Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information

video

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, explains how Flatiron analytics help practices succeed in value ...

video

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, discusses how the clinical data set at Flatiron helps ...

video

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, discusses how technology is helping reform the way community ...

video

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, talks about how CMMI is changing the health care ...

video

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

Mike Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, explains the impact of the ACA on the insurance ...

video

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses how practices and administrators can build higher pathway compliance

video

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, explains how clinical pathways differ from clinical guidelines

video

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses if clinical pathways create value in cancer care

video

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, explains how clinical pathways save money when treating cancer

video

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, on how oncology practices consume patient-reported data to improve patient ...

video

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, on potential solutions available for practices to implement better patient ...

video

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

Maddy Herzfeld, R.N., B.S.N., O.C.N., Chief Executive Officer, Carevive Systems, discusses the challenges practices are facing when implementing patient engagement

video

Bobby Green, MD, on leveraging genomic testing into actionable data

Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, on leveraging genomic testing into actionable data

video

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, discusses how Flatiron and Foundation Medicine work together to combine genomic ...

video

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

Bobby Green, MD, Senior VP, Clinical Oncology, Flatiron Health, explains if genomic data can be used to prescreen patient eligibility ...

video

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, explains his vision for how GPOs must evolve in the era of value-based ...

video

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, discusses best practices that a GPO can implement to help with value-based savings

video

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, on how important the drug channel is compared to reduction in hospitalizations

video

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

Jeffrey Scott, MD, Chief Medical Officer, IntegraConnect, shares the highest-impact areas of focus for value-based care savings, inside and outside ...

video

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, on whether the ACA changed access to care at New England ...

video

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, explains how New England Cancer Specialists helps patients get access to ...

video

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, on why this is a challenging time for oncology practices

video

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, talks about what technology his practice adopted to participate in OCM

video

Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists

Steve D’Amato, R.Ph., Executive Director, New England Cancer Specialists, talks about data capture and data analytics at New England Cancer ...

video

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, on the differences working with hospital-based cancer centers versus community oncology practices

video

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

Diana Verrilli, Vice President/General Manager Managed Care, McKesson Specialty Health, on how claims data can be used to help practices ...

video

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

Diana Verrilli, Vice President/General Manager Managed Care, McKesson Specialty Health, on how claims data is being used to change patterns ...

video

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, discusses how limited distribution impacts the delivery ...

video

Ira Klein, MD, explains how risk management changes the way we manage supply chain

Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, explains how risk management changes the way ...

video

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, explains the challenges for oncologists and practices with the OCM model

video

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

Ed Bassin, Ph.D., Chief Analytics Officer, Archway Health, tells us what oncologists should be thinking about today as they approach ...

video

Ira Klein, MD, on what the shift toward oral oncolytics means for the supply chain

Ira Klein, M.D., M.B.A., Senior Director Quality, Strategic Customer Group, Janssen Pharmaceutical Companies, on what the shift toward oral oncolytics ...

video

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

Dave Terry, Chief Executive Officer, Archway Health, explains why practices should participate in Alternative Payment Models

video

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

Dave Terry, Chief Executive Officer, Archway Health, shares his thoughts on Alternative Payment Models of the future

video

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

Dave Terry, Chief Executive Officer, Archway Health, on the keys to success when participating in Alternative Payment Models

video

Debra Patt, MD, on what tele-health brings to cancer care

Dr. Patt, Vice President, Texas Oncology, on what tele-health brings to cancer care

video

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

Dr. Bosserman, City of Hope Medical Foundation, on how a practice should decide whether to participate in MIPS or an ...

video

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

Dr. Bosserman, City of Hope Medical Foundation, explains “Pick Your Pace” as it relates to participation in MACRA

video

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

Dr. Patt, Vice President, Texas Oncology, explains using predictive analytics to improve cancer care delivery

video

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

Dr. Patt, Vice President, Texas Oncology, explains how decision support tools improve the quality and delivery of cancer care

video

James Hamrick, MD, explains how EMRs help connect patients and caregivers

Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, explains how EMRs help connect patients and caregivers

video

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, on how cancer care ...

video

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, explains what City of ...

video

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains the requirements that must ...

video

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, shares her thoughts on the ...

video

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, on using real world evidence to learn how to ...

video

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, on the philosophy for ...

video

Harlan Levine, MD, tells us about the continuous cycle of learning and improving at City of Hope

Dr. Levine, Chief Strategy Officer, City of Hope and Chief Executive, City of Hope Medical Foundation, tells us about the ...

video

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains how an episode of ...

video

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

Lili Brillstein, M.P.H., Director Episodes of Care, Horizon Blue Cross Blue Shield of New Jersey, explains the primary goal of ...

video

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

Dr. Bosserman, City of Hope Medical Foundation, discusses the highlights of the MACRA panel at CCBS 2017

video

Linda Bosserman, MD, explains what MACRA means for oncologists today

Dr. Bosserman, City of Hope Medical Foundation, explains what MACRA means for oncologists today

video

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

Dr. Patt, Vice President, Texas Oncology, explains how data systems are helping with patient care delivery in community oncology

video

James Hamrick, MD, shares his thoughts on how we are evolving toward a learning health care system

Dr. Hamrick, Practicing Community Oncologist and Senior Medical Director, Flatiron Health, shares his thoughts on how we are evolving toward ...

video

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses which molecular tests to order for ...

video

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC ...

video

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients

video

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on which molecular tests to order for a newly diagnosed ...

video

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and ...

video

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, talks about the DFCI wellness study demonstrating that CRC patients ...

video

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the ...

video

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how checkpoint inhibitors are being integrated into treatment of ...

video

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how to integrate genetic mutations, and left sided vs ...

video

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on whether resected pancreatic cancer patients should be offered adjuvant ...

video

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage ...

video

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, discusses which molecular tests to order when determining treatment approach ...

video

John L. Marshall, MD, talks about the results of the RESORCE trial

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, talks about the results of the RESORCE trial and how ...

video

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how new agents being studied for advanced HCC will be integrated into ...

video

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, discusses the outcomes of the RESORCE trial as presented here at ASCO GI ...

video

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on reliably identifying subgroups of patients for targeted therapies in HCC

video

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC

video

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on identifying subgroups of HCC patients that ...

video

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

video

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on whether physicians will incorporate regorafenib into clinical practice

video

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on if the RESORCE trial will change ...

video

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use ...

video

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the quality of life data from the NETTER-1 study

video

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the results of the NETTER-1 study

video

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

Dr. Hochster, Associate Director, Yale Cancer Center, differentiates regorafenib from 5FU and TAS-102 from a mechanism of action perspective

video

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC ...

video

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

Dr. Hochster, Associate Director, Yale Cancer Center, on integrating immunotherapy into existing treatment regimens for GI cancer patients

video

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a ...

video

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

Dr. Hochster, Associate Director, Yale Cancer Center, discusses if genetic profiling has changed the approach to treating CRC patients

video

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, explains how new agents in advanced HCC are being integrated into treatment

video

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses the outcomes of the RESORCE trial

video

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses how checkpoint inhibitors be incorporated into the treatment of unresectable HCC

video

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, shares his thoughts on whether physicians will incorporate regorafenib into clinical practice

video

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, on identifying subgroups of patients for targeted therapies in HCC

video

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, shares her thoughts on some exciting trials or drugs ...

video

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, discusses some of the challenges in treating pancreatic cancer

video

Johanna Bendell, MD, discusses the RESORCE trial data

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, provides her expectations on how the RESORCE trial data ...

video

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the Proprietary Neoantigen Identification Technology platform

video

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses how new agents being studied for ...

video

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains the outcomes of the RESORCE trial ...

video

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, shares her thoughts on whether physicians will ...

video

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted ...

video

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains how checkpoint inhibitors will be incorporated ...

video

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, talks about how integrating immunotherapy into existing treatment regimens for CRC ...

video

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how organoids are being used for cancer biology research

video

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses integrating immunotherapy into existing treatment regimens for GI cancer ...

video

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, discusses the goals of the NCI-MATCH trial and the progress to ...

video

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the outcomes of the randomized phase 2 study in ...

video

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the phase 3 study in advanced gastric ...

video

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains which molecular tests help determine treatment approach

video

Edith P. Mitchell, MD, on how classifications of gastric cancer subtypes are impacting treatment

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how new classifications of gastric cancer subtypes based on molecular ...

video

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how the Blue Ribbon Panel may help with the Cancer ...

video

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, talks about ...

video

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, weighs in ...

video

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, provides insight ...

video

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains the ...

video

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains how ...

video

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides viewpoint on how physicians should sequence ...

video

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on exciting news coming out of ASH ...

video

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides opinion on if the word “cure” ...

video

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, discusses optimism about the use of immunotherapies ...

video

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on if payers are using clinical pathways in ...

video

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on which ASH 2016 CLL presentations have caught ...

video

Alexander Perl, MD, discusses treatment options for AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, weighs in on AML treatment options in patients ...

video

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, ...

video

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, gives his feedback on trials looking at treatment ...

video

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on which ASH AML trial results have been ...

video

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on intriguing data for CLL coming out of ASH 2016

video

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses the latest updates in T cell lymphomas that is being presented ...

video

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, talks about exciting new treatment options for CLL

video

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses the best way for physicians to manage MRD negative patients

video

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, talks about which and why, multiple myeloma patients should be tested for ...

video

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on the current treatment algorithm for smoldering myeloma patients

video

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses his optimism around the use of of immunotherapies treatment for multiple ...

video

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on the incorporation of immunotherapies into treatment algorithms ...

video

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

Dr. Prince, Professor, The University of Melbourne and Monash University, on how he expects CTCL patients to be impacted by ...

video

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

Dr. Prince, Professor, The University of Melbourne and Monash University, on ASH 2016 positive news for CTCL patients

video

David Miklos, MD, on developing an orphan drug for a small population of patients

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, relays his pharmaceutical company experience in developing an ...

video

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, on which clinical advances in CLL ...

video

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, on big changes discovered in the ASH meetings in ...

video

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the new drugs worth mentioning

video

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, talks about how important drug ...

video

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, discusses ...

video

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains how to integrate stem cell transplantation into the treatment of ...

video

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, talks about how stem cell transplant figures into the treatment algorithm ...

video

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speaks to which stem cell transplantation studies are most exciting and ...

video

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, speaks ...

video

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, talks ...

video

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, provides ...

video

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses which ASH 2016 presentations were the ...

video

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

Dr. Kauffman, CEO Karyopharm Therapeutics, discusses the regulatory and commercialization plans for Selinexor

video

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, relays ...

video

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, explains how immunotherapies are being integrated into multiple myeloma treatment algorithms

video

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on personalized medicine and its impact on the treatment ...

video

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on what physicians should be aware of when ...

video

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, provides his thoughts on whether multiple myeloma can be cured one day

video

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, explains how the CPX 351 data may impact the market and how ...

video

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, on ...

video

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, gives her view on exciting ...

video

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses how romidepsin should be incorporated into the treatment of patients with ...

video

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, talks about the outcomes in his ...

video

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, speaks about the unmet medical need ...

video

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, on how stem cell and bone marrow transplant ...

video

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, explains the phase 2 ibrutinib study outcomes for ...

video

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on her findings of the most exciting news ...

video

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

Dr. Winter, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, weighs in on how personalized medicine is being applied ...

video

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on how physicians should base treatment decisions on MRD test results for ...

video

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on what he found to be the most exciting news at ASH ...

video

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on how physicians should incorporate ofatumumab into the treatment of untreated CLL ...

video

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, talks about how the BEAT AML master trial ...

video

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on how molecular testing can be used to ...

video

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, relays the end goals for the multiple ...

video

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on how the multiple myeloma genome project ...

video

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the role of selinexor and the STORM ...

video

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, discusses challenges and strategies to ...

video

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, talks about the advances in CLL and the ...

video

Edward Copelan, MD, discusses the Levine Cancer Institute Program

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, talks about his Levine Cancer Institute program

video

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, discusses the results of the ZUMA-1 pivotal phase ...

video

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, explains what the results of ZUMA-1 mean to ...

video

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses what new targets could make ...

video

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses the results of the ZUMA-1 ...

video

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

Dr. Prince, Professor, The University of Melbourne and Monash University, talks about the outcomes of the ALCANZA study in CD30-expressing ...

video

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, shares her thoughts on the advancements in the treatment of leukemia ...

video

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, provides insight on how elderly patients with hematological ...

video

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how clinical pathways are being incorporated into ...

video

Michael Kauffman, MD, on how Selinexor works

Dr. Kauffman, CEO Karyopharm Therapeutics, on how Selinexor works

video

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

Dr. Kauffman, CEO Karyopharm Therapeutics, explains the clinical evidence on Selinexor that is helping relapsed, refractory multiple myeloma patients

video

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he reduced the number of ...

video

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in T-cell lymphomas presented at ...

video

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in cutaneous lymphomas presented at ...

video

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, discusses CPX 351 in older high-risk patients in AML

video

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, talks about the importance of the AGIOS 221 data

video

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks bout the key takeaways from ASH 2016 presentation ...

video

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, discusses the latest developments in stem cell transplantation here at ASH ...

video

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains the effectiveness of novel immunotherapies in the treatment of multiple ...

video

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, discusses CLL presentations at ASH 2016

video

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, shares his thoughts on the most exciting treatment options available in multiple ...

video

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses venetoclax and why it stands out as one of the most ...

video

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses selinexor (KPT-330) and why it stands out as one of the ...

video

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, explains the importance of ...

video

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her thoughts on investigational drugs in ...

video

Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment

Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, discusses regimen preference in mCRC 1st line ...

video

Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI

Skip Burris, MD, President, Clinical Operations, Sarah Cannon Research Institute, talks about how CAR-Ts work, and the trials taking place ...

video

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on how ...

video

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, provides feedback on new agents being studied for advanced HCC and ...

video

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about progress being made developing ...

video

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center talks on how PD-L1 ...

video

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the different approaches being studied to make ...

video

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

Robert Figlin, MD, Steven Spielberg Chair in Hematology-Oncology, discusses recent clinical advances, including overall survival benefit, when treating renal cell ...

video

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses treatment strategies because of ...

video

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides insights into ...

video

Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients

Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center explains how PD-L1 inhibitors and other immunotherapies are being developed for the ...

video

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses optimal dosage for Stivarga (regorafenib) in the 2nd ...

video

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on patient ...

video

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, discusses the importance ...

video

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective on immunotherapy and how ...

video

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center shares ...

video

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

Phil Bonomi, MD, Professor, Rush University Medical Center, talks about the evolving role of targeted agents, such as ramucirumab, in 2nd ...

video

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine answers the reliability of MSI-High as a predictor of response ...

video

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, on which classes and products in development look promising for the ...

video

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, discusses the response rates and PFS for longer ...

video

Laura Chow, MD discusses incorporating checkpoint inhibitors into standard of care

Laura Chow, MD, Associate Professor, Medical Oncology, University of Washington School of Medicine, discusses incorporating checkpoint inhibitors into standard of ...

video

Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients

Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, talks about the progress made in selecting ...

video

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the evolving development ...

video

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

Anthony El-Khoueiry, MD, Associate Professor of Clinical Medicine, Kenneth Norris Comprehensive Cancer Center, discuss products being developed for hepatocellular carcinoma ...

video

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on testing ...

video

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the economic versus efficacy outcomes in CALGB/SWOG ...

video

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, answers whether long term response rate and PFS ...

video

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

video

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, highlights some key data at the ASCO ...

video

Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)

Value tools, i.e. the ASCO Value Framework and the NCCN Evidence Blocks, received a lot of attention at ASCO ’16. ...

video

Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN

Laura Chow, MD, Associate Professor, University of Washington School of Medicine, provides the rationale for studying PD-L1 inhibitors in recurrent ...

video

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, relays the importance of ...

video

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, relays the long term data specific to the ...

video

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

Jeffrey Weber, MD, PhD, Co-Director of Melanoma Program, NYU Langone Medical Center, discusses the efficacy of checkpoint inhibitors and immunotherapy ...

video

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, provides interpretation of the ...

video

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, talks about the importance of considering performance status when selecting therapy ...

video

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on utilizing regorafenib (Stivarga) and trifluridine (Lonserf) in 3rd line ...

video

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, discusses the importance of giving ipilimumab (Yervoy) prior to nivolumab (Opdivo) ...

video

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, shares on the reliability of Microsatellite instability-High (MSI-High) as a predictor ...

video

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

Tanios Bekali-Saab, MD, Professor of Medicine, Mayo Clinic, comments on whether KRAS can be used to determine treatment approaches knowing ...

video

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...

video

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...

video

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

Phil Bonomi, MD, Professor, Rush University Medical Center, shares his thoughts on the potential importance of checkpoint inhibitors in the ...

video

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

Phil Bonomi, MD, Professor, Rush University Medical Center, shares his thoughts on the costs of new lung cancer therapies relative to ...

video

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, discusses the role of CDK ...

video

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on the ...

video

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, comments on the results of ...

video

Mark Levis, MD, discusses significance of the Quantum-R study

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...

video

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...

video

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on why ...

video

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on the ...

video

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the concept of ...

video

Julie Gralow, MD, on the KRISTINE study

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comment on the KRISTINE study of preoperative ...

video

Julie Gralow, MD, discusses the Monarch 1 study

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comments on the Monarch 1 study of ...

video

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, discusses the outcomes of the PALOMA-2 trial ...

video

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine provides practical advise for ...

video

Julie Brahmer, MD, on the importance of overall cost of therapy

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discusses the importance of ...

video

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine shares her perspective on ...

video

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on new drugs in ...

video

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on liquid biopsy as ...

video

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on the PALOMA-2 randomized ...

video

Eunice S. Wang, MD, discusses the Quantum First Study

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, comments on the Quantum First Study, ...

video

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute talks about Crenolanib and its activity in ...

video

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why sustained inhibition may be important ...

video

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why FLT3 is important and provides ...

video

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective on immunotherapy and how ...

video

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine discussed with OBR ...

video

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine talks about when ...

video

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, shares his perspective ...

video

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the application of ...

video

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

During the 2016 ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why specificity ...

video

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why sustained inhibition may be important in ...

video

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on immunotherapy and it may ...

video

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center discusses results of nivolumab (Opdivo) ...

video

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center, talks about the management of ...

video

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

Anthony El-Khoueiry, MD, Associate professor of Clinical Medicine at the Kenneth Norris Comprehensive Cancer Center, talks about changes in HCC ...

video

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

video

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania talks about Crenolanib and its activity in ...

video

Alexander Perl, MD, discusses the Quantum First Study and potential implications

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, comments on the Quantum First Study, ...

video

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why sustained inhibition may be important ...

video

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why potency may be important in ...

video

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why FLT3 is important and provides ...

video

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, highlights some key data at the ASCO ...

video

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center discusses ...

video

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine talks about when agents ...

video

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discussed with OBR practical ...

video

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

During the ASCO meeting, Julie Brahmer, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine discusses the potential future ...

video

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, discusses the potential ...

video

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

Mark Levis, MD, on why the FLT3 target is important in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on why ...

video

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

During the ASCO meeting, David Ettinger, MD, Alex Grass Professor in Oncology, Johns Hopkins School of Medicine, provides practical advice ...

video

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, on the phase 3 CALGB/SWOG 80405 study outcomes regarding primary ...

video

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, discusses treatment changes due to primary site of tumor overall ...

video

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on if left versus right-sided primary tumor provides a predictive ...

video

Howard Hochster, MD on performance status importance in selecting treatment algorithms

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine weighs in on performance status importance in determining treatment algorithms ...

video

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine discusses how the economic benefit seen in CALGB/SWOG 80405 compares ...

video

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on the non MSI-High immunotherapy development progress for CRC patients

video

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, provides feedback on the rationale for studying PD-L1 inhibition in advanced ...

video

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, discusses which late stage clinical studies could potentially impact the standard ...

video

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, discusses the unique toxicities that physicians are seeing ...

video

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, discusses if there is a stopping point where, ...

video

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, agrees there will be broad use of immunotherapies ...

video

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

video

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective progress being made toward selecting the right patient ...

video

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on immunotherapy in CRC and what clinicians can ...

video

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

Jennie R. Crews, MD, Medical Director at PeaceHealth St. Joseph Cancer Center, provides her perspective on how the Institute for ...

video

Tanios Bekaii-Saab, MD, on outcomes of CALGB/SWOG 80405 regarding primary site of tumor

Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of ...

video

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, explains how to integrate Stivarga (regorafenib) and Lonserf (trifluridine) ...

video

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses the importance of giving Yervoy (ipilimumab) prior to ...

video

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on the reliability of MSI-High as a predictor of ...

video

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses phase 3 CALGB/SWOG 80405 study outcomes regarding primary ...

video

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

Philip Phillip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute on what is impressing him at ASCO 2016 in ...

video

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

Nevena Damianov, MD, Section Chief Hematology/Oncology, University of Pennsylvania, discusses the main toxicity concerns and how to manage with the ...

video

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center relays the pipeline’s ...

video

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center on the results ...

video

Laura Chow, MD tells us about products in development for SCCHN

Laura Chow, MD, Associate Professor, University of Washington School of Medicine, provides some insight into the products in the pipeline ...

video

Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers

Laura Chow, MD, Associate Professor, Medical Oncology, University of Washington School of Medicine, discusses cross trial comparisons with Keytruda (pembrolizumab) ...

video

Laura Chow, MD discusses the role of PD-L1 testing in SCCHN

Laura Chow, MD, Associate Professor, University of Washington School of Medicine, discusses the role of PD-L1 testing in squamous cell ...

video

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

Jeffrey Weber, MD, PhD, Deputy Director and Co-Director of Melanoma Program at NYU Langone Medical Center, explains the long term ...

video

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses the top PD-1 or PD-L1 inhibitor treatment ...

video

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, provides the big picture ...

video

Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy

Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center on how toxicities factor into decision making for later ...

video

Barbara Burtness, MD talks about new patient treatment insights based on the Keynote-055 study

Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine on if response rates by anatomic site in the ...

video

Barbara Burtness, MD explains if the Keynote-012 study confirms the benefit seen with Keytruda

Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine explains if updated data confirms the Keynote-012 study durable ...

video

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses the KEYNOTE-O10 study of ...

video

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center discussed ...

video

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses ...

video

Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study

Laura Chow, MD, Associate Professor, University of Washington School of Medicine, interprets the overall survival benefit with Opdivo (nivolumab) in ...

video

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about whether the phase 3 ...

video

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides his perspective ...

video

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center relays the outcomes of the ...

video

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

Robert Figlin, MD, Steven Spielberg Chair in Hematology-Oncology, discusses the challenge in treating 2nd line kidney cancer and how he ...

video

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, explains how cabozantinib can fit into renal cell carcinoma (RCC) treatment ...

video

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, provides a clinical study update on the use of nivolumab (Opdivo®) ...

video

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center on reaffirmation of efficacy ...

video

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on the ...

video

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center describes how hormonal therapies ...

video

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment